Looking back, what a journey! We remember well when we first started working with Thomas Baumert in late 2017. Built on many years of transformational…
Synendos is developing first-in-class inhibitors. These inhibitors modulate a newly identified drug target in the body’s endocannabinoid system which is a key neuromodulator system in…
Polyneuron Pharmaceuticals, a BaseLaunch portfolio company, has concluded the extension of its Series A financing round. With further investment of 14 million francs, the startup has…
This second closing of CHF 4.7M is led by BioMedPartners AG and Altos Ventures AG, who are joining the previous investors Redalpine Venture Partners AG,…
Versameb also welcomes Dr. Klaas P. Zuideveld as Chief Development Officer. Prior to Versameb he was Vice President of Partnerships at Caris Life Sciences, and…
The orphan drug designation can only be granted for treatments on rare diseases to advance the developments of safe and effective therapies and the FDA…
PharmaBiome also welcomed two new board members with extensive biotech and entrepreneurial experience, all the way from founding to IPO. Dr. Thomas Meier joins PharmaBiome…